Orientadores: Lucia Regina Durrant, Alexandre Nunes Ponezi / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Engenharia de Alimentos / Made available in DSpace on 2018-08-20T15:30:45Z (GMT). No. of bitstreams: 1 Santos_IvanJoseSantana_M.pdf: 1134875 bytes, checksum: 88af103bdbd26ade9ec5e063cbd582c5 (MD5) Previous issue date: 2012 / Resumo: 17a-etinilestradiol (EE2), carbamazepina (CBZ) e ibuprofeno (IBU) são substâncias farmacêuticas muito utilizadas em todo o mundo e vêm sendo frequentemente detectadas em estações de tratamento de efluentes e em águas naturais em vários países, inclusive no Brasil. A grande preocupação da presença destes fármacos em quantidades residuais na água potável e nos ambientes aquáticos são os potenciais efeitos adversos para a saúde humana e animal. O objetivo principal deste trabalho foi avaliar o potencial de fungos ligninolíticos e bactérias para degradar esses três compostos, individualmente. Linhagens de bactérias e fungos ligninolíticos foram crescidas em meio mineral com os fármacos, na presença ou ausência de glicose. Primeiramente, foi realizada uma seleção com o objetivo de escolher linhagens bacterianas e fúngicas com maior capacidade de degradação dessas drogas, avaliando a necessidade da presença de glicose para que a degradação ocorresse. As linhagens que apresentaram maior capacidade de degradar tais compostos foram selecionadas e, em seguida, foram realizados ensaios com o intuito de se otimizar o período de incubação, visando-se uma maior porcentagem de degradação no menor período de incubação possível. Posteriormente, foram realizadas análises de atividade das enzimas lacase, lignina peroxidase (LiP) e manganês peroxidase (MnP) produzidas pelos fungos selecionados e foi avaliada a participação dessas na degradação dos fármacos. A atuação das enzimas do Citocromo P450 na degradação dos fármacos foi avaliada por meio da adição de piperonil butóxido (PB), o qual inibe esse complexo enzimático. A toxicidade dos fármacos e seus metabólitos para a bactéria Vibrio fischeri também foram avaliadas. A quantificação dos fármacos em todas as amostras foi realizada por meio de cromatografia líquida de alta eficiência. EE2 foi totalmente degradado por todos os fungos avaliados, sem a necessidade de glicose no meio de cultivo; no entanto, nenhuma das bactérias estudadas foi capaz de degradá-lo significativamente. Pleurotus ostreatus (Jacq.) P. Kumm linhagem P1 foi selecionado para os ensaios subsequentes. Após 6 dias, foi encontrada atividade de MnP igual a 5122,11 U.L-1. A lacase teve como atividade 307,69 U.L-1, valor encontrado após 4 dias de incubação. Não foi detectada atividade da enzima LiP em nenhum dos tempos analisados. Apesar da detecção de atividade dessas enzimas, elas não foram capazes de degradar o EE2 na ausência do micélio fúngico. Nos ensaios de toxicidade foi encontrada uma CE50 igual a 76% para o EE2 e os metabólitos não apresentaram toxicidade. Trametes sp. linhagem BNI foi a selecionado para degradar CBZ, sendo a glicose necessária para o processo de biodegradação. Após 28 dias de incubação, houve 42% de degradação de CBZ. A atividade máxima de lacase foi de 1740,17 U.L-1, sendo encontrada após 21 dias de incubação. LiP teve como atividade máxima 663,08 U.L-1, valor encontrado após 14 dias de incubação. Não foi detectada atividade da enzima MnP em nenhum dos tempos analisados. Não houve a degradação de CBZ utilizando apenas o caldo enzimático. A presença de PB inibiu totalmente a degradação de CBZ. CBZ e seus metabólitos não apresentaram toxicidade. Nenhuma das bactérias foi capaz de degradar CBZ. IBU foi totalmente degradado por todos os fungos avaliados sem a necessidade de glicose no meio de cultivo, sendo Trametes sp. linhagem BNI selecionado para os ensaios posteriores. Após 2 dias de incubação, BNI foi capaz de degradar totalmente IBU. Lacase foi a única enzima que teve atividade detectada nesse ensaio, sendo a atividade máxima detectada igual a 478,18 U.L-1, no sexto dia de incubação. Não foi detectada degradação de IBU utilizando apenas o caldo enzimático e a presença de PB no meio não inibiu a degradação deste fármaco. Nos ensaios de toxicidade foi encontrada uma CE50 igual a 86% para o IBU e os metabólitos não apresentaram toxicidade. Staphylococcus arlettae e Bacillus megaterium foram capazes de degradar significativamente IBU na presença de glicose. B. megaterium foi selecionado para os ensaios subsequentes. Após 3 dias, essa linhagem foi capaz de degradar todo IBU disponível no meio. Nos ensaios de toxicidade para os metabólitos do processo de biodegradação por B. megaterium, o IBU apresentou uma CE50 inicial igual a 47% e os metabólitos não apresentaram toxicidade. Esses resultados comprovam que fungos ligninolíticos e bactérias são capazes de degradar fármacos encontrados em matrizes ambientais, sendo plausível a utilização destes micro-organismos, ou suas enzimas, em sistemas de tratamento de água e esgoto / Abstract: 17a-ethinylestradiol (EE2), carbamazepine (CBZ) and ibuprofen (IBU) are pharmaceutical drugs used worldwide and have been frequently detected in wastewater treatment plants and in natural waters in several countries, including Brazil. The major concern about the occurrence of these drugs in trace amounts in drinking water and aquatic environments are the potential adverse effects on human and animal health. The main objective of this study was to assess the potential of ligninolytic fungi and bacteria to degrade these 3 compounds individually. Bacteria and ligninolytic fungi strains were grown on mineral medium with these drugs and with or without glucose. A selection was carried out to choose bacterial and fungal strains with capacity to degrade these drugs and if an addition of a carbon source (glucose) was needed for degradation. Strains with greater capacity to degrade these compounds were selected and assays were performed in order to optimize the incubation time to obtain the highest degradation rate in the shortest incubation time. Subsequently, the enzymatic activities of laccase, lignin peroxidase (LiP) and manganese peroxidase (MnP) produced by the selected fungi was assessed. Also, the action of these enzymes in the degradation of the drugs was evaluated. The involvement of cytochrome P450 enzymes in degradation of the pharmaceutical drugs was evaluated by the addition of piperonyl butoxide (PB), which inhibits this enzyme complex. The toxicity of the drugs and metabolites to Vibrio fischeri were also evaluated. The quantification of the drugs was performed by high performance liquid chromatography. EE2 was completely degraded by all fungi without glucose in the medium, however none of the studied bacteria was capable to degrade it significantly. Pleurotus ostreatus (Jacq.) P. Kumm strain P1 was selected for subsequent tests. The maximum enzyme activity produced by P1 was 5122.11 UL-1 for MnP after 6 days and 307.69 UL-1 for lacase after 4 days, while LiP activity was not detected. Although the detection of the enzymes activity, they were not able to degrade EE2 without the fungal mycelia. Toxicity studies showed the half maximal effective concentration (EC50) value equal to 76% to EE2 prior to fungal treatment, after this no toxicity was observed. Trametes sp. strain BNI was selected to degrade CBZ, and glucose was shown to be necessary for the biodegradation process. After 28 days of incubation, 42% of CBZ was degraded. The maximum laccase activity was 1740.17 UL-1, after 21 days of incubation. LiP maximum activity was 663.08 UL-1, found after 14 days of incubation, while MnP activity was not detected. There was no CBZ degradation using only the enzymatic supernatant. The addition of PB completely inhibited the degradation of CBZ. CBZ and its metabolites did not show toxicity. IBU was completely degraded by all fungi without glucose in the medium, and Trametes sp. strain BNI was selected for further analyses. 17a-ethinylestradiol (EE2), carbamazepine (CBZ) and ibuprofen (IBU) are pharmaceutical drugs used worldwide and have been frequently detected in wastewater treatment plants and in natural waters in several countries, including Brazil. The major concern about the occurrence of these drugs in trace amounts in drinking water and aquatic environments are the potential adverse effects on human and animal health. The main objective of this study was to assess the potential of ligninolytic fungi and bacteria to degrade these 3 compounds individually. Bacteria and ligninolytic fungi strains were grown on mineral medium with these drugs and with or without glucose. A selection was carried out to choose bacterial and fungal strains with capacity to degrade these drugs and if an addition of a carbon source (glucose) was needed for degradation. Strains with greater capacity to degrade these compounds were selected and assays were performed in order to optimize the incubation time to obtain the highest degradation rate in the shortest incubation time. Subsequently, the enzymatic activities of laccase, lignin peroxidase (LiP) and manganese peroxidase (MnP) produced by the selected fungi was assessed. Also, the action of these enzymes in the degradation of the drugs was evaluated. The involvement of cytochrome P450 enzymes in degradation of the pharmaceutical drugs was evaluated by the addition of piperonyl butoxide (PB), which inhibits this enzyme complex. The toxicity of the drugs and metabolites to Vibrio fischeri were also evaluated. The quantification of the drugs was performed by high performance liquid chromatography. EE2 was completely degraded by all fungi without glucose in the medium, however none of the studied bacteria was capable to degrade it significantly. Pleurotus ostreatus (Jacq.) P. Kumm strain P1 was selected for subsequent tests. The maximum enzyme activity produced by P1 was 5122.11 UL-1 for MnP after 6 days and 307.69 UL-1 for lacase after 4 days, while LiP activity was not detected. Although the detection of the enzymes activity, they were not able to degrade EE2 without the fungal mycelia. Toxicity studies showed the half maximal effective concentration (EC50) value equal to 76% to EE2 prior to fungal treatment, after this no toxicity was observed. Trametes sp. strain BNI was selected to degrade CBZ, and glucose was shown to be necessary for the biodegradation process. After 28 days of incubation, 42% of CBZ was degraded. The maximum laccase activity was 1740.17 UL-1, after 21 days of incubation. LiP maximum activity was 663.08 UL-1, found after 14 days of incubation, while MnP activity was not detected. There was no CBZ degradation using only the enzymatic supernatant. The addition of PB completely inhibited the degradation of CBZ. CBZ and its metabolites did not show toxicity. IBU was completely degraded by all fungi without glucose in the medium, and Trametes sp. strain BNI was selected for further analyses / Mestrado / Ciência de Alimentos / Mestre em Ciência de Alimentos

Over the recent years, increasing scientific attention has been paid to pharmaceuticals, other drugs and their metabolites. These substances are of particular interest because of their physiological, toxicological and ecotoxicological effects in the human body and respectively in the environment. Cytochrome P450 enzymes (P450s) play a key role in the conversion and detoxification of bioactive compounds including many pharmaceuticals and drugs. Most of these enzymes belong to the monooxygenases; they are intracellular and rather unstable biocatalysts that are difficult to purify and require expensive, complex cofactors, which alltogether hampers their use in isolated form. The investigations carried out here with fungal peroxygenases have shown that this enzyme sub-subclass (EC 1.11.2.x) has a promising potential for oxyfunctionalizations and can catalyze a variety of reactions typical for P450s. Peroxygenases are extracellular, i.e. secreted fungal enzymes with high stability, which merely need peroxide for function. Results obtained with the unspecific/aromatic peroxygenases (APOs) of Agrocybe aegerita, Coprinellus radians and Marasmius rotula have demonstrated that APOs catalyze numerous H2O2-dependent monooxygenations of pharmaceuticals and psychoactive drugs. Among them are i) the monooxygenation of aromatic compounds, ii) the benzylic hydroxylation of toluene derivatives, iii) the O-dealkylation of different ether structures including the scission of benzodioxoles (O-demethylenation) and esters as well as iv) the N-dealkylation of secondary and tertiary amines. The peroxygenases studied considerably differ in their substrate spectrum and the preferred positions of oxidation. This finding opens the possibility to develop in the future an “enzymatic toolbox“ on the basis of fungal peroxygenases for the oxyfunctionalization of pharmaceutically relevant compounds. Mechanistic studies showed that (1) the monooxygenations always proceed via incorporation of one oxygen atom from the peroxide, (2) the demethylation of phenacetind1 established a deuterium isotope effect similar to P450s, (3) the catalytic efficiencies for the studied oxidations are in the same range as those of P450s (though the kcat- and Km values are noticeably higher), (4) the kinetic studies with nitro-1,3-benzodioxole gave parallel double reciprocal plots suggestive of a “ping pong” mechanism, (5) the substrate spectrum and the activity pattern of APOs follows in a wide range those of the human key P450s as well as that (6) the difference spectra obtained in bindings studies are of the phenol type of P450s. Furthermore, APOs were found to be stable and active in long term experiments over two weeks and they oxidized pharmaceuticals at low, environmentally relevant concentration (ppb range). All the above properties strongly indicate that APOs respresent an interesting alternative for the enzymatic conversion of pharmaceuticals as well as for the preparation of human drug metabolites, for example, in medicinal and pharmacological research or the bioremediation sector (removal of pharmaceuticals from environmental media). / In den letzten Jahren sind Pharmazeutika und deren Metabolite mehr und mehr in den Fokus der Wissenschaft gerückt. Diese Substanzen sind aufgrund ihrer physiologischen und toxikologischen sowie ökotoxikologischen Wirkungen im menschlichen Körper bzw. in der Umwelt von besonderem Interesse. Cytochrom-P450-Enzyme (P450s) spielen eine Schlüsselrolle bei der Umsetzung und Detoxifizierung bioaktiver Substanzen, darunter vieler Pharmazeutika und Drogen. Es handelt sich bei diesen Enzymen in erster Linie um Monooxygenasen, die intrazellulär lokalisiert und relativ instabil sind; sie benötigen komplexe, teure Kofaktoren und sind nur unter hohem Aufwand zu reinigen, was ihre Anwendung in isolierter Form insgesamt erschwert. Die hier durchgeführten Untersuchungen zu pilzlichen Peroxygenasen haben gezeigt, dass diese Enzymsubklasse (EC 1.11.2.x) ein hohes Oxyfunktionalisierungspotenzial besitzt und eine Vielzahl P450-typischer Reaktionen zu katalysieren vermag. Peroxygenasen sind extrazelluläre, d.h. sekretierte Pilzenzyme, die eine hohe Stabilität aufweisen und lediglich ein Peroxid als Kosubstrat benötigen. Die unter Verwendung der unspezifischen/aromatischen Peroxygenasen (APOs) von Agrocybe aegerita, Coprinellus radians und Marasmius rotula gewonnenen Ergebnisse belegen, dass APOs verschiedene H2O2-abhängige Monooxygenierungen von Pharmazeutika und psychoaktiven Substanzen realisieren. Dazu gehören i) die Monooxygenierung von Aromaten, ii) die benzylische Hydroxylierung von Toluolderivaten, iii) die O-Dealkylierung verschiedener Etherstrukturen einschließlich der Spaltung von Benzodioxolen (O-Demethylenierung) und Estern sowie iv) die N-Dealkylierung von sekundären und tertiären Aminen. Die untersuchten Peroxygenasen wiesen teilweise deutliche Unterschiede im Substratspektrum und den präferierten Oxidationspositionen auf. Dieser Befund eröffnet die Möglichkeit, zukünftig einen „enzymatischen Werkzeugkasten“ auf Basis pilzlicher Peroxygenasen für die Oxyfunktionalisierung von pharmazeutisch relevanten Wirkstoffen zu entwickeln. Mechanistische Experimente zeigten, dass (1) die Monooxygenierungen stets unter Einbau eines aus dem Peroxid stammenden Sauerstoffatoms erfolgen, (2) die Deethylierung von Phenacetin-d1 einen Deuteriumisotopeneffekt ähnlich dem der P450s aufweist, (3) die katalytischen Effizienzen für die untersuchten Oxidationen im gleichen Bereich wie die der P450s liegen (wobei die kcat- und Km-Werte deutlich höher ausfallen), (4) die kinetischen Untersuchungen zur Oxidation von Nitro-1,3-Benzodioxol parallele Verläufe der ermittelten Ausgleichsgeraden in der doppelt reziproken Darstellung ergaben, was für einen “Ping-Pong-Mechanismus“ spricht, (5) sich das Substratspektrum und die Aktivitätsmuster der APOs in einem weiten Bereich mit denen der wichtigsten menschlichen P450s decken sowie dass (6) die in Bindungsstudien gewonnenen Differenzspektren denen des Phenoltyps der P450s entsprechen. Desweiteren erwiesen sich APOs in Langzeitexperimenten über zwei Wochen als stabil und aktiv und sie waren in der Lage, Pharmazeutika in umweltrelevanten Konzentrationen (ppb-Bereich) zu oxidieren. All die genannten Eigenschaften legen nahe, dass APOs eine interessante Alternative zur enzymatischen Umsetzung von Pharmazeutika sowie zur Herstellung von humanen Pharmazeutika-Metaboliten darstellen, die z.B. Einsatz in der medizinischpharmakologischen Forschung oder im Umweltbereich (Entfernung von Pharmazeutika aus Umweltmedien) finden könnten.